Literature DB >> 24697342

Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.

Cyrielle Dumont1, Marylore Chenel, France Mentré.   

Abstract

Nonlinear mixed-effect models are used increasingly during drug development. For design, an alternative to simulations is based on the Fisher information matrix. Its expression was derived using a first-order approach, was then extended to include covariance and implemented into the R function PFIM. The impact of covariance on standard errors, amount of information, and optimal designs was studied. It was also shown how standard errors can be predicted analytically within the framework of rich individual data without the model. The results were illustrated by applying this extension to the design of a pharmacokinetic study of a drug in pediatric development.

Keywords:  D-optimality; Fisher information matrix; Nonlinear mixed effect models; Optimal design; PFIM; Pediatric studies; Population pharmacokinetics

Mesh:

Substances:

Year:  2014        PMID: 24697342     DOI: 10.1080/10543406.2014.888443

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  3 in total

1.  Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.

Authors:  Cyrielle Dumont; France Mentré; Clare Gaynor; Karl Brendel; Charlotte Gesson; Marylore Chenel
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

2.  Assessing robustness of designs for random effects parameters for nonlinear mixed-effects models.

Authors:  Stephen B Duffull; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-10-24       Impact factor: 2.745

3.  CORE GREML for estimating covariance between random effects in linear mixed models for complex trait analyses.

Authors:  Xuan Zhou; Hae Kyung Im; S Hong Lee
Journal:  Nat Commun       Date:  2020-08-21       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.